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A B S T R A C T
Background
Accruing evidence from observational and epidemiological studies suggests an inverse relationship between dietary intake of omega 3
polyunsaturated fatty acid (PUFA) and risk of dementia. Postulated mechanisms that might qualify omega 3 PUFA as an interven-
tional target for the primary prevention of dementia include its anti-atherogenic, anti-inflammatory, anti-oxidant, anti-amyloid and
neuroprotective properties.
Objectives
To review the evidence that omega 3 PUFA supplementation prevents cognitive impairment and dementia in cognitively intact elderly
persons.
Search methods
The Cochrane Dementia and Cognitive Improvement Group’s (CDCIG) Specialized register, MEDLINE, EMBASE,CINAHL
PsycINFO, AMED AND CENTRAL and several ongoing trials databases were searched on 5 and 6 October 2005. The CDCIG
Register is updated regularly and contains records from all major medical databases and many ongoing trials databases.
Selection criteria
In order to be selected, trials needed to be randomized, placebo-controlled, doubled blinded, of minimum study duration of 6 months,
involved persons aged 60 years and above without pre-existing dementia at study onset, and employed cognitive endpoints.
Data collection and analysis
Reviewers, working independently, were to select, quality assess and extract relevant data where appropriate and possible. In comparing
intervention with placebo, the pooled odds ratios or weighted mean differences and standardized mean difference were to be estimated.
Main results
There were no randomized trials found in the search that met the selection criteria. Results of two clinical trials are expected in 2008.
1Omega 3 fatty acid for the prevention of dementia (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Authors’ conclusions
There is a growing body of evidence from biological, observational and epidemiological studies that suggests a protective effect of
omega 3 PUFA against dementia. However, until data from randomized trials become available for analysis, there is no good evidence
to support the use of dietary or supplemental omega 3 PUFA for the prevention of cognitive impairment or dementia.
P L A I N L A N G U A G E S U M M A R Y
There is no evidence that dietary or supplemental omega 3 polyunsaturated fatty acid (PUFA) reduces the risk of cognitive
impairment or dementia in healthy elderly persons without pre-existing dementia
Evidence from biological and epidemiological studies suggests that lower omega 3 PUFA intake is associated with an increased risk
of dementia. In experimental animal models, dietary enhancement of docosahexanoic acid (a long-chain omega 3 PUFA) slows the
expression of Alzheimer’s pathology and improves cognitive performance. These findings raise the possibility of similar preventative
benefits in humans. Omega 3 PUFA have also being shown to reduce vascular risk, inflammation and oxidative damage. Available
clinical studies comparing the occurrence of Alzheimer’s disease between elderly persons with different levels of dietary omega 3 PUFA
intake, suggest that risk of Alzheimer’s disease is significantly reduced among those with higher levels of fish and omega 3 PUFA
consumption. However, because these studies are not randomized trials, they provide insufficient evidence to recommend dietary and
supplemental omega 3 PUFA for the explicit purpose of dementia prevention.
This review yielded no clinical trials that could confirm or refute the utility of omega 3 PUFA in preventing cognitive impairment or
dementia. This is an important area that is in pressing need of further research.
B A C K G R O U N D
Congruent with the graying demographic trend in many devel-
oped countries, it is projected that there will be an exponential rise
in the prevalence of age-associated diseases like dementia. It has
been estimated, based on demographic projections, that between
1990 and 2010, the number of cases of Alzheimer’s disease (AD)
in developed countries will rise by nearly 40%. Dementia is a pro-
gressive debilitating syndrome that imposes a huge burden of care
on individual caregivers, health care professionals, and resource
utilization, especially institutionalized care. Current therapeutic
approaches do not reverse the progression of the disease, and of-
ten only offer short-term symptomatic improvement (Cummings
2004). In the current economic climate of increasing health care
costs and tightening health care budgets, there is a pressing need
for effective preventative measures of dementia.
Studies suggest that the pathogenesis of dementia involves the
complex interactions between genetic and environmental risk fac-
tors. In recent years, there has been an increased interest in nutri-
tion as an important modifiable environmental risk factor. Nutri-
ents and metabolites such as folic acid, vitamin B12, vitamin B6
and homocysteine have been the focus of attention (Nourhasémi
2000). This interest has widened to encompass the investigation
of an implicating role of low omega 3 polyunsaturated fatty acid
(PUFA) status in the etiology of dementia. This is supported by
studies suggesting that omega 3 PUFA consumption may be ben-
eficial in the treatment of other neuropsychiatric conditions such
as depression (Hibbeln 1998) and bipolar affective disorder (Stoll
1999).
Omega 3 PUFAs have been in the limelight since the astute ob-
servation by Bang in the 1970s that the Greenland Inuit had low
mortality from coronary artery disease despite a diet that is rich in
fat (Bang 1971). It was proposed that this could be because of the
high content of omega 3 fatty acid in the Inuit diet, which con-
sisted largely of fish, seal and whale (Dyerberg 1975). The marine
sources of omega 3 PUFA (also called n-3 PUFA) include eicos-
apentanoic acid (EPA or 20:5), docosahexanoic acid (DHA, 22:6)
and docosapentanoic acid (DPA, 22:5), which are the longer chain
omega 3 forms. Alpha linolenic acid (ALA, 18:3) is the shorter
chain omega 3 fatty acid fromnuts and vegetable oils. Although an
endogenous process exists whereby ALA can be partially converted
to the longer chain omega 3 fatty acids, there is some debate about
the effectiveness of this conversion, depending on other dietary
factors and whether assessed over short or long term. For this rea-
son, the effectiveness of ALA may differ from that of the longer
chain forms (Hooper 2004).
Several mechanisms have been postulated for the protective role of
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omega 3 PUFA in dementia. Firstly, omega 3 PUFA may protect
against dementia by reducing cardiovascular disease (Tully 2003)
andnon-haemorrhagic stroke risk (He 2002; Iso 2001).Cardiovas-
cular disease has been shown to increase the risk of dementia and
its major subtypes, AD and vascular dementia (Hofman 1997).
The beneficial effects of long chain PUFA in reducing vascular risk
include antiarrhythmic, antithrombotic, anti-inflammatory and
antiatherogenic effects (Friedland 2003).Omega 3PUFAmay also
lower serum triglyceride levels, lower blood pressure and improve
endothelial function (Din 2004). Secondly, omega 3 PUFA may
reduce dementia risk by reducing the synthesis of pro-inflamma-
tory cytokines, and thereby, attenuate the pro-inflammatory com-
ponents of the dementia disease process (Akiyama 2000). Thirdly,
since DHA is a primary component of membrane phospholipids
in the brain, adequate omega 3 PUFA status may protect against
dementia by themaintenance ofmembrane integrity and neuronal
function. In animal models, dietary enhancement of DHA was
shown to promote neuronal membrane excitability, increase neu-
rotransmitter levels, and reduce neuronal damage (Morris 2003b).
In behavioural models, this translated into superior learning ac-
quisition and memory performance over animals fed control diets
(Calon 2004; Gamoh 1999). Lastly, omega 3 PUFA may play a
pivotal role in the expression of ß-amyloid, a major component of
the hallmark plaque pathology in Alzheimer’s disease, by reducing
its production from amyloid precursor protein and increasing its
clearance (Friedland 2003).
A cross-sectional study reported that higher fatty fish and ma-
rine omega 3 PUFA consumption was associated with a reduced
risk of impaired cognitive performance in a middle-aged popu-
lation (Kalmijn 2004). Corroborative evidence of an inverse re-
lationship between fish or omega 3 PUFA intake and risk of
dementia can be found in observational (Conquer 2000; Tully
2003; Ruggiero 2004) and epidemiological studies (Barberger-
Gateau2002; Huang 2005; Kyle 1999; Morris 2003a; Morris
2003b). The epidemiological studies are large population-based
studies with a prospective design and reasonable duration of follow
up (3.9 to 10 years). However, several methodological concerns
deserve mention. In the Chicago Health and Aging Project, the
self-reported food frequency questionnaire was administered just 2
years before clinical diagnosis of dementia (Morris 2003a; Morris
2003b). Thus, bias from subclinical dementia cannot be excluded;
the observed association with omega 3 PUFA levels may be a con-
sequence of altered dietary habits rather than a cause of cognitive
decline. In the PAQUID (Personnes Ageés QUID) study, dietary
data was limited to only 4 frequencies of intake without collect-
ing information for specific fat groups, and vitamin E intake was
not adjusted for in the analysis (Barberger-Gateau2002). The Car-
diovascular Health Cognition Study likewise did not adjust for
vitamin E in the analysis; also, adjustment by education and in-
come attenuated the benefits of fatty fish on dementia risk (Huang
2005). Lastly, the results of Kyle et al were preliminary and only
presented in a one-page research letter with few methodological
details (Kyle 1999).
Moreover, the evidence of an inverse relationship between omega
3 PUFA intake and risk of dementia is not unambiguous.While an
inverse association between cognitive decline with age and omega
3 PUFA was reported in a population-based study that examined
fatty acid composition of erythrocyte membranes (Heude 2003),
this was not replicated in a recent prospective cohort study that
utilised dietary questionnaire to assess fatty acid intake (Morris
2005). This study found that dietary intake of fish was associated
with slower cognitive decline with age over a 6 year follow-up,
although there was no consistent association with omega 3 fatty
acids, suggesting the possibility that the protective effect of fatty
fish consumption may not be fully accounted for by omega-3
PUFA. The Rotterdam study did not demonstrate any influence
of low omega 3 PUFA intake on dementia risk after amean follow-
up of 6 years, thereby not confirming the positive findings of an
earlier report on the same study which was based on a shorter
follow up of 2 years and a smaller number of incident dementia
cases (Kalmijn 1997; Engelhart 2002). Likewise, the Canadian
Study of Health and Aging did not find any beneficial effects from
omega 3 PUFA (Laurin 2003). In addition, interventional studies
of omega 3 fatty acids in dementia are limited, and tend to be
small in numbers and of short follow up duration (Terano 1999;
Yehuda 1996). Larger scale clinical interventional trials examining
the effect of increased omega 3 intake on coronary artery disease
tend not to examine dementia risk or cognition endpoints.
Given that most omega-3 PUFA are ingested in the form of oily
fish or fish oil capsules, reports of environmental contamination
with various toxic compounds such as mercury, dioxin and poly-
chlorinated biphenyls (PCBs) are disconcerting. Adult exposures
to dioxins and PCBs may lead to an excess of total cancers, while
high mercury levels in some fish species may attenuate their car-
dioprotective effects (Guallar 2002). A recent Cochrane review
did not demonstrate an adverse effect of dietary or supplemen-
tal omega-3 PUFA on total mortality, combined cardiovascular
events or cancers in people with or at high risk of cardiovascular
disease, and in the general population (Hooper 2004). Some re-
ports show that fish oil may worsen glycemic control in diabetes,
but two meta-analyses found no adverse effect (Friedberg 1998;
Montori 2000).
The cumulative summation of many small protective effects of
omega 3 PUFA may add up to a significant protective effect on
dementia risk and age-related cognitive decline. Thus, this sys-
tematic review aims to pool together the evidence to examine the
effect of omega 3 PUFA in the primary prevention of dementia in
the non-demented population.
O B J E C T I V E S
Primary
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To determine from available evidence whether dietary or supple-
mental omega 3 fatty acid is effective in the primary prevention
of dementia in non-demented older persons.
Secondary
To review the benefit of treatment with omega 3 fatty acid on
cognition measures, and whether its protective effect (if any) is
dependent on the dose.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review is restricted to all randomized controlled trials (RCTs)
in non-demented participants where omega 3 PUFA was com-
pared with placebo, provided that there was a minimum follow up
of 6 months (26 weeks or 180 days) and dementia was excluded at
baseline. Studies which do not have cognitive endpoints (defined
as either incident dementia or measurement on a cognition rating
scale or instrument) are excluded.
There is no restriction on language, publication type and sample
size. Trials are excluded if the allocation of treatment and placebo
was not random.
If a study meets all the criteria for inclusion but does not present
sufficient data allowing an estimate of effect (and this informa-
tion is not available from the authors), the study is treated as a
“dropout” instead of being excluded, and listed in a table of eligi-
ble studies to indicate that it has not been overlooked.
Types of participants
Eligible participants include persons aged 60 years and above,
without a diagnosis of dementia or cognitive impairment at study
onset. The chief consideration for the age cut-off is to ensure a
characteristic representation of the neurodegenerative diseases that
are typically seen in older persons (such as Alzheimer’s disease), as
the heterogeneous subset of young onset dementias are often due
to underlying illnesses that are very different in etiology, presenta-
tion, and rate of progression from that encountered in the elderly
population.
Subjects with a diagnosis of delirium and acute confusion at study
onset are excluded.
There should be a demonstration of adequate screening to exclude
pre-existing dementia or cognitive impairment via the use of cog-
nitive instruments, dementia rating scales or psychometric tests
that have been reported in peer-reviewed journals. Subjects with
known cognitive impairment but not amounting to dementia are
excluded from this review. These include (but are not limited to)
the following diagnostic categories: dementia prodrome, incipient
dementia, cognitive impairment no dementia (CIND), mild cog-
nitive impairment (MCI), vascular cognitive impairment (VCI),
age-associated memory impairment (AAMI), and age associated
cognitive decline (AACD). While some of these terms were con-
ceptually meant to characterize memory changes reflecting a “nor-
mal” stage of aging, more recent data has cast some doubt on this
premise (Ritchie 2000). In particular, MCI has been recognized
as a diagnostically heterogeneous entity with a significant progres-
sion to dementia (Petersen 2001).
There is no restriction on the basis of gender, ethnicity, study
setting or other characteristics.
Types of interventions
Any type of omega 3 PUFA treatments, as monotherapy or in
combination with other pharmacological treatment (including vi-
tamins), if the design allows the effect of omega 3 PUFA to be
isolated. There are broadly two types of omega 3 treatment of rel-
evance:
i) longer chain omega 3 PUFA: eicosapentanoic acid (EPA), do-
cosahexanoic acid (DHA) or docosapentanoic acid (DPA), either
individually or in combination, and/or
ii) shorter chain PUFA such as alpha linolenic acid (ALA).
The intervention should involve dietary supplementation or a pro-
vided diet. There is no restriction on dose or dosing schedule.
Studies are excluded if the intervention consisted solely of dietary
advice, or if the interventionwas based solely on self report without
definitive provision of dietary supplements (usually in the form of
pills or oils) or a diet. In studies where the intervention consisted
of a provided diet, these would still be eligible if treatment was
compared with usual diet. Otherwise, trials where treatment was
compared with another active treatment and not to a placebo, are
excluded.
Studies are also excluded if they include multiple risk factor inter-
vention on lifestyle factors other than diet and supplementation
(unless the effect of diet or supplementation can be separated out
from the other interventions).
Types of outcome measures
Primary outcome
Incident dementia of any cause as defined by accepted interna-
tional diagnostic criteria, such as those of the International Classi-
fication of Diseases (ICD-10: WHO 1992), American Psychiatric
AssociationDiagnostic and StatisticalManual ofMentalDisorders
(DSM III-R; DSM-IV), and the National Institute of Neurologi-
cal and Communicative Disorders and Stroke and the Alzheimer’s
disease and Related Disorders Association (NINCDS-ADRDA:
McKhann 1984).
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Secondary outcomes
Mean change in measures of memory and cognitive function from
baseline to follow-up as measured by peer-reviewed mental sta-
tus tests such as the Mini-Mental State Examination (MMSE),
or more detailed psychometric assessment such as the Wechsler
Memory Scale.
Proportion reporting progression using peer reviewed global rating
scales such as the Clinical dementia Rating (CDR).
Mean change in measures of validated health-related quality of life
such as the SF-36 (Ware 1993).
Behavioural outcomes relating to depression and anxiety using ac-
cepted international criteria such as the DSM criteria, or validated
rating scales such as the Geriatric Depression Scale (Gompertz
1993), Hamilton Depression Inventory and Hamilton Anxiety
Rating scale (Hamilton 1960), Hospital Anxiety and Depression
Scale (Zigmond 1983), the Beck Depression Inventory and Beck
Anxiety Inventory (Beck 1961).
As studies without cognitive endpoints will be excluded, health-
related quality of life and mood outcomes will be collected only
if present along with cognitive endpoints. Where available, out-
comes of explanatory interest such as treatment dose, and blood
levels of PUFA status (such as cholesteryl ester-EPA) are collected.
Search methods for identification of studies
The Cochrane Dementia and Cognitive Improvement Group’s
Specialised Register was searched on 5 October 2005 using the
terms: Omega-3 or Omega 3 or Polyunsaturated fatty acid or
PUFA or unsaturated fatty acids or Essential fatty acids or EFA or
Eicosapentanoic acid or EPA or Ethyl-Eicosapentanoic acid or E-
EPA or Docosahexanoicacid or DHA or Docosapentanoic acid or
DPA or Alpha-linolenic acid or ALA or Fish oil or n-3 fatty acids
or long chain fatty acids or primrose oil or linseed oil or oily fish
or flaxseed oil or fish oil.
CENTRAL (Cochrane Library issue 3, 2005) was searched on 5
October 2005 using the following search strategy:
MEDLINE (1966-2005/10, week 1) was searched on 5 October
using the following search strategy:
#1 explode “Fatty-Acids-Omega-3”/ all subheadings
#2 “fatty acid*” or fats or omega-3 or “omega 3” or PUFA or EPA
or E-EPA or DHA or DPA or ALA
#3 n-3-fatty-acid* or “n-3 fatty acid*” or “linseed oil” or “flaxseed
oil” or “fish oil” or “salmon oil” or “cod liver oil”
#4 “eicosapentanoic acid*” or “docosahexanoic acid*” or “dosapen-
tanoic acid*” or “alpha-linolenic acid*” or “ethyl-eicosapentanoic
acid*”
#5 #1 or #2 or #3 or #4
#6 explode “Primary-Prevention”/ all subheadings
#7 prevent* or avoid*
#8 #6 or #7
#9 #5 and #8
#10 cognit*
#11 #9 and cognit*
#12 #11 and (healthy or normal or elderly or older)
EMBASE (1980-2005/09) was searched on 6 October using the
following search strategy:
#1 explode “fatty-acid”/ all subheadings
#2 “fatty acid*” or fats or omega-3 or “omega 3” or PUFA or EPA
or E-EPA of DHA or DPA or ALA
#3 n-3-fatty acid* or “n-3 fatty acid*” or “linseed oil” or “flaxseed
oil” or “fish oil” or “salmon oil” or “cod liver oil”
#4 “eicosapentanoic acid*” or “docosahexanoic acid*” or “dosapen-
tanoic acid*” or “alpha-linolenic acid*” or “ethyl-eicosapentanoic
acid*
#5 ”#1 or #2 or #3 or #4
#6 “primary-prevention”/ all subheadings
#7 prevent* or avoid*
#8 #6 or #7
#9 #5 and #8
#10 #9 and (healthy or normal or elderly or older)
#11 #10 and (random* or placebo* or double-blind*)
#12 #11 and cognit*
PsycINFO (1872-2005/09, week 4) was searched on 6 October
using the following search strategy:
#1 explode “Fatty-Acids”
#2 “fatty acid*” or fats or omega-3 or “omega 3” or PUFA or EPA
or E-EPA or DHA or DPA or ALA
#3 n-3-fatty-acid* or “n-3 fatty acid*” or “linseed oil” or “flaxseed
oil” or “fish oil” or “salmon oil” or “cod liver oil”
#4 “eicosapentanoic acid*” or “docosahexanoic acid*” or “dosapen-
tanoic acid*” or “alpha-linolenic acid*” or “ethyl-eicosapentanoic
acid*”
#5 #1 or #2 or #3 or #4
#6 “Primary-Mental-Health-Prevention” in MJ,MN
#7 prevent* or avoid*
#8 #6 or #7
#9 #5 and #8
#10 #9 and (healthy or normal or elderly or older)
#11 #10 and cognit*
CINAHL (1982-2005/08) was searched on 6 October using the
following search strategy:
#1 explode “Fatty-Acids-Omega-3”/ without-subheadings , ad-
ministration-and-dosage , adverse-effects , antagonists-and-in-
hibitors , analysis , blood , cerebrospinal-fluid , classification , con-
traindications , drug-effects , diagnostic-use , economics , ethi-
cal-issues , history , immunology , immunology , legislation-and-
jurisprudence , metabolism , pharmacodynamics , physiology ,
pharmacokinetics , poisoning , radiation-effects , standards , ther-
apeutic-use , urine / without-subheadings , in-adolescence , in-
adulthood , in- infancy-and-childhood , in-old-age , in-pregnancy
, in-utero
#2 “fatty acid*” or fats or omega-3 or “omega 3” or PUFA or EPA
or E-EPA or DHA or DPA or ALA
#3 n-3-fatty-acid* or “n-3 fatty acid*” or “linseed oil” or “flaxseed
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oil” or “fish oil” or “salmon oil” or “cod liver oil”
#4 “eicosapentanoic acid*” or “docosahexanoic acid*” or “dosapen-
tanoic acid*” or “alpha-linolenic acid*” or “ethyl-eicosapentanoic
acid*”
#5 #1 or #2 or #3 or #4
#6 “Preventive-Trials”/ without-subheadings , adverse-effects ,
classification , economics , education , ethical-issues , equipment-
and-supplies , evaluation , history , immunology , legislation-and-
jurisprudence , methods , organizations , standards , trends , ther-
apeutic-use , utilization / without-subheadings , in-adolescence ,
in-adulthood , in-infancy-and- childhood , in-old-age , in-preg-
nancy , in-utero
#7 prevent* or avoid*
#8 #6 or #7
#9 #5 and #8
#10 #9 and (healthy or normal or elderly or older)
#11 #10 and (random* or placebo* or double-blind*)
#12 #11 and cognit*
AMED (1985-2005/09) was searched on 6 October using the
following search strategy:
#1 explode “FATTY-ACIDS”
#2 “fatty acid*” or fats or omega-3 or “omega 3” or PUFA or EPA
or E-EPA or DHA or DPA or ALA
#3 n-3-fatty-acid* or “n-3 fatty acid*” or “linseed oil” or “flaxseed
oil” or “fish oil” or “salmon oil” or “cod liver oil”
#4 “eicosapentanoic acid*” or “docosahexanoic acid*” or “dosapen-
tanoic acid*” or “alpha-linolenic acid*” or “ethyl-eicosapentanoic
acid*”
#5 #1 or #2 or #3 or #4
#6 “PREVENTION-” in DE,ET,MT
#7 prevent* or avoid*
#8 #6 or #7
#9 #5 and #8
#10 #9 and (healthy or normal or elderly or older)
#11 #10 and cognit*
ClinicalTrials.gov and NRR (National Research Register - http://
www.update-software.com/projects/nrr/) were searched for ongo-
ing trials on 6 October 2005. The search engines Copernic and
Google were used with the search terms omega, trial, cognition on
the same date.
The following electronic databases (all years) were also searched
on 27 September 2006 using the terms: Omega-3 or Omega 3
or Polyunsaturated fatty acid or PUFA or unsaturated fatty acids
or Essential fatty acids or EFA or Eicosapentanoic acid or EPA or
Ethyl-Eicosapentanoic acid or E-EPA or Docosahexanoicacid or
DHA or Docosapentanoic acid or DPA or Alpha-linolenic acid
or ALA or Fish oil or n-3 fatty acids or long chain fatty acids
or primrose oil or linseed oil or oily fish or flaxseed oil or fish
oil. Where appropriate, the search was narrowed using the terms:
“prevent*” or “avoid*”; “dementia”; “randomized controlled trial”
or “clinical study”.
• :AgeLine Databases
• Alt-HealthWatch (alternative medicine)
• Biological Abstracts[R]
• BioMed Central
• Clinical Pharmacology Database
• DIMDI (european research)
• Dissertation Abstracts
• HerbMed (alternative medicine)
• HSTAT (Health Services Technology Assessment Text
• Web of Science
In addition, review bibliographies of books and review articles,
and references from retrieved articles were explored. Experts in this
field were also contacted for further references and unpublished
trials.
There were no time restrictions or language constraints applied.
Data collection and analysis
When studies are available for analysis, the following methods will
be applied:
Study selection
Based on the title of publication and the abstract identified from
the trial search, irrelevant citations will be discarded by the review-
ers (WL, AD, JG and JVN). If there is any possibility that the
article could be relevant, the full text article will be retrieved for
further assessment. Two reviewers (WL, JG or JVN) will indepen-
dently decide which trials fit the inclusion criteria. Any disagree-
ment will be resolved by discussion between the reviewers, with
referral to a third reviewer to adjudicate any persisting differences.
Excluded studies and reasons for exclusion will be stated.
Assessment of methodological quality
Although there are a number of scales devised for assessing the
quality of RCTs, there is no evidence that complex and time-con-
suming scales are more effective than simple scales. The following
areas have some evidence of association with biased estimates of
treatment effect (Juni 2001), and will be assessed:
a) randomization (method of generation and concealment of al-
location)
b) blinding (blinding of observers / participants to the treatment
allocation)
c) loss to follow-up (presence of withdrawals and loss to follow up,
and the analysis of these).
The quality assessment will include an evaluation of the following
components for each included study. Each component will be
categorized as Adequate, Unclear, Inadequate, or Not Used, based
on the following:
• Randomization (allocation generation) - adequate when the
allocation sequence protects against biased allocation to the
comparison groups
• Randomization (allocation concealment) - adequate when
measures are taken to ensure that decision for recruitment
precedes knowledge of allocation
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• Blinding - adequate when the outcome assessor is unaware
of the allocation
• Loss to follow up - adequate if less than 20% of participants
withdrew from the trial, or were lost to follow up
• Intention to treat analysis - adequate when participants were
analysed in the groups to which they were originally randomized
On the basis of the above criteria, trials will be given a quality
rating of A (adequate), B (unclear), and C (inadequate), based
on the quality categories as described in the Cochrane Reviewers’
Handbook 4.2.2. (Alderson 2004). A description of the quality
of each study will be given based on a summary of the above
components.
Data Extraction
This will be performed by two reviewers (AD, JG or JVN), who
will independently enter data onto a data extraction form. The
extracted data will be checked for agreement between reviewers,
and any discrepancies that persist after discussion will be resolved
by a third reviewer (WL). Missing data will be obtained from the
authors whenever possible. To avoid introducing bias, this unpub-
lished information will be obtained in writing, on forms designed
for this purpose. The data will then be entered into Review Man-
agement software (RevMan 4.2).
The following data will be collected:
• Report - author, year and source of publication
• Study - study setting, sample characteristics
• Patients - demographics, screening to exclude pre-existing
cognitive impairment or dementia, absence of acute confusion or
delirium at study onset, other concomitant medical conditions
or medications that may affect cognition
• Research design and features - sampling mechanism,
treatment assignment mechanism, blinding, drop-out rates,
length of follow-up, pertinent design features (e.g. crossover
design)
• Intervention - type, duration, dose, timing, mode of
delivery
• Outcome - number of patients randomized, nature of
outcome, estimate and standard error, adverse effects, reason for
non-adherence, measurement of omega-3 status
For continuous data, the summary statistics required for each out-
come are the mean change from baseline, the standard deviation
of the mean change, and the number of patients in each treat-
ment group at each assessment. Where changes from baseline are
not reported, the mean, the standard deviation and number of
patients for each treatment group at each time point will be ex-
tracted if available. For binary data, the numbers in each treatment
group and the numbers experiencing the outcome of interest will
be sought. The baseline assessment is defined as the latest available
assessment prior to commencement of intervention.
To allow an intention-to-treat analysis, the data will be sought ir-
respective of compliance, whether or not the patient was subse-
quently deemed ineligible, or otherwise excluded from treatment
or follow-up. If intention-to-treat data are not available in the pub-
lications, “on-treatment” data, or the data of those who completed
the trial, will be sought and indicated as such.
In studies where a cross-over design was used, only data from
the first treatment phase after randomization will be eligible for
inclusion.
Data Analysis
For binary outcomes, such as presence or absence of dementia,
Peto odds ratio and its 95% confidence interval (CI) will be used
to measure treatment effect. The number needed to treat (NNT)
will also be calculated. In addition, a weighted estimate of the
typical treatment effect across trials will be calculated.
With regards to outcomes measured arising from ordinal rating
scales, these will be treated as continuous variables if the ordinal
scale appears to be approximately normally distributed or if the
analysis suggests parametric tests are appropriate. If the normal
approximation is not deemed appropriate, the study will be re-
garded as a “dropout” rather than ineligible, and will be listed in
a table of eligible studies.
For continuous variables, summary statistics (number of partic-
ipants, mean and standard deviation) will be required for each
outcome of each treatment group for change from baseline. For
crossover trials only the data from the first treatment period will
be used. When change from baseline results are not reported, the
required summary statistics will be calculated from the baseline
and assessment time treatment group means and standard devi-
ations. In this case a zero correlation between the measurements
at baseline and assessment time will be assumed. This method
overestimates the standard deviation of the change from baseline,
but this conservative approach is considered to be preferable in a
meta-analysis.
The measure of the treatment difference for any outcome will
be the weighted mean difference when the pooled trials use the
same rating scale or test. Where different rating scales or tests are
used, the trial specific summary effect will be transformed to a
standardized (scale-free) mean difference, which is calculated as
the absolute mean difference divided by the standard deviation.
Overall estimates of the treatment difference will be presented. A
fixed-effects model will be used in the first instance but if there is
evidence of heterogeneity, then either only homogeneous results
will be pooled, or a random-effects model will be used (in which
case the confidence intervals would be broader than those of a
fixed-effects model).
If numbers permit, subgroup analysis will be performed to ex-
amine the impact of dose, composition (e.g. marine versus plant
sources), baseline cognitive function (e.g. baseline MMSE) and
whether Omega 3 PUFA supplementation was in isolation or an
adjunct to other therapy. Reasons for heterogeneity in studies will
be explored and, if necessary, sensitivity analyses will examine the
effects of excluding study subgroups, e.g. those studies with lower
methodological quality. If study numbers permit, a funnel plot
will be used to detect publication bias.
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R E S U L T S
Description of studies
See: Characteristics of excluded studies; Characteristics of ongoing
studies.
Our search yielded only 2 randomized trials in elderly persons
with cognitive endpoints (Terano 1999; Yehuda 1996). Both are
treatment trials in patients with established Alzheimer’s disease or
vascular dementia, and thus, not applicable to our review. There
are no randomized trials examining the primary prevention of
cognitive decline or dementia.
However, there are two ongoing randomized controlled trials with
cognitive endpoints of omega 3 PUFA supplementation in healthy
cognitively intact older persons thatmay be relevant to a future up-
date of the review. The OPAL study (Dangour 2004) is a double-
blind randomized placebo-controlled trial examining the effect
of daily supplementation with 700 mg omega 3 PUFA (500 mg
DHA and 200 mg EPA) for 24 months on cognitive performance
in healthy older persons aged 70-79 with good cognitive function
(MMSE equals or greater than 24 out of 30 points at baseline)
who are recruited from 20 primary care practices. It is scheduled
for completion at the end of 2007. Secondly, there is the MEMO
study (van de Rest 2005), which is scheduled for completion in
end 2007. Elderly persons aged 65 years and above with baseline
MMSE greater than 21will be randomized to one of three groups:
400 mg EPA-DHA, 2 g EPA-DHA or placebo oil in capsules.
Excluded studies
We did not consider a recently concluded study which examined
the effects of 3-month EPA/DHA supplementation on depressed
mood and cognitive function in adults aged 20-65 as participants
were too young to meet inclusion criteria (Rogers 2005). There is
another ongoing randomized trial in healthy young adults (Singhal
2004) that is also of an inappropriate age group for the purposes
of our review.
Risk of bias in included studies
Not applicable
Effects of interventions
There is no evidence that omega 3 PUFA reduce the risk of cog-
nitive impairment or dementia.
D I S C U S S I O N
Not applicable
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
On the basis of currently available evidence, omega 3 PUFA sup-
plementation cannot be recommended for the explicit purpose of
preventing cognitive impairment or dementia.
However, it is not uncommon in clinical practice to encounter
well-meaning patients and their families who specifically enquire
about dietary recommendations for lowering the risk of dementia.
Evidence from large well-conducted population studies suggests
that a high intake of saturated or trans-unsaturated fats increases,
while fatty fish and marine
omega 3 PUFA consumption decreases the risk of cognitive im-
pairment and incident dementia (Barberger-Gateau2002;Kalmijn
2004; Morris 2003a; Morris 2003b). Thus, in this regard, it is
not unreasonable to encourage adequate consumption of fatty fish
as part of general dietary recommendations that may also confer
benefits of reducing the risk of stroke and heart disease (Friedland
2003).
Implications for research
Although biological and epidemiological studies support the util-
ity of omega 3 PUFA in preventing cognitive impairment or de-
mentia, there is a pressing need for randomized double-blind
placebo-controlled trials to confirm or refute this premise. While
risk reduction is an important measure, there are other issues in
need of investigation. These include:
• The effects of omega 3 PUFA on sub-populations
• The effects of omega 3 PUFA source
• Optimal dose and exposure duration
• Sustenance of effect after cessation of omega 3 PUFA
supplementation
• Whether there is a differential benefit on dementia risk for
those with APOE-epsilon 4 compared with those without
(Huang 2005).
• Whether omega 3 PUFA supplementation can retard or
stop the progression of disease diagnosed at an early, mild stage
(i.e. secondary prevention treatment trials)
• Whether therapy started in middle life has an advantage
over therapy started in the 60s or early 70s.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Rogers 2005 This study has been completed; write-up is pending results of blood fatty acid assays. However, via personal commu-
nication (October 2005) we know the triallists recruited only younger age adults (20-65 years) with mild to moderate
depression
Singhal 2004 This is an ongoing study scheduled for completion 30 Sep 2006. Recruited only younger age participants
Characteristics of ongoing studies [ordered by study ID]
Dangour 2004
Trial name or title Older People And n-3 Long-chain poluunsaturated fatty acids
Methods
Participants Healthy, cognitively normal (baseline MMSE greater than 23) adults aged 70-79 years.
Recruited from 20 general practices.
Interventions 1. 0.7g n-3 oil (0.5g DHA/0.2g EPA) daily for 24 months
2. Placebo
Outcomes 1. California Verbal Learning Test (primary outcome)
2. Immediate and delayed recall
3. Verbal fluency
4. Digit span backwards
5. Digit symbol
6. Spatial memory
7. Timed letter search
8. Simple and choice reaction time
9. Prospective memory
10. Dual-task performance
Starting date 01/03/2004
Contact information Dr Alan Dangour
London School of Hygiene and Tropical Medicine
Keppel Street
London
United Kingdom
WC1E 7HT
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Dangour 2004 (Continued)
Notes
van de Rest 2005
Trial name or title Mental Health in Elderly Maintained with Omega-3
Methods
Participants Older persons aged >65 years with baseline MMSE >21
Interventions 1. 400mg EPA-DHA for 26 weeks
2. 2g EPA-DHA for 26 weeks
3. Placebo
Outcomes 1. RAVLT Rey Auditory Verbal learning test (primayr outcome)
2. Weschler forward and backward digit span
3. Trails A and B
4. Stroop test
5. Fluency test
6.. Quality of life
(WHOQOL-BREF)
Starting date 01/10/2005
Contact information Ondine van de Rest
Division of Human Nutrition
Wageningen University
Postbus 8129
Wageningen
6700 EV
Netherlands
Notes
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 11 November 2005.
Date Event Description
6 November 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 1, 2006
Date Event Description
12 November 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
WL: initiated and drafted the protocol. He will be involved in trial search and selection, adjudication of disagreements in data extraction,
data entry, statistical analyses, and writing of the final review.
JG, JVN, AD: provided an equal input into the conceptual development and editing of the protocol, and was involved in data
interpretation and review of the final draft.
Both JG and JVN also searched trials, selected trials, and extracted data, while AD was involved in data extraction.
Contact Editor: Peter Whitehouse
Consumer Editor: Christine Derrick
This review has been peer reviewed in November 2005.
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D E C L A R A T I O N S O F I N T E R E S T
Alan Dangour is the principal investigator of the Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) study.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Cognition Disorders [∗prevention & control]; Dementia [∗prevention & control]; Fatty Acids, Omega-3 [∗therapeutic use]; Random-
ized Controlled Trials as Topic
MeSH check words
Aged; Humans
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